Idiopathic Pulmonary Fibrosis Pipeline 2025: Mechanism of Action, Route of Administration, and Clinical Trial Insights Explored by DelveInsight | FibroGen, MediciNova, Pliant Therapeutics, Horizon Pharma, Reviva Pharma, Roche, Vicore Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Idiopathic Pulmonary Fibrosis pipeline constitutes 80+ key companies continuously working towards developing 100+ Idiopathic Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Idiopathic Pulmonary Fibrosis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Idiopathic Pulmonary Fibrosis Market.

Some of the key takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report: https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Idiopathic Pulmonary Fibrosis treatment therapies with a considerable amount of success over the years.
• Idiopathic Pulmonary Fibrosis companies working in the treatment market are FibroGen, MediciNova, Pliant Therapeutics, Horizon Pharmaceuticals, Reviva Pharmaceuticals, Roche, Vicore Pharma, Aria Pharmaceuticals, InSilico Medicine, AdAlta, AstraZeneca, Lung Therapeutics, CSL Behring, Galecto Biotech AB, Pliant Therapeutics, Endeavor BioMedicine, FibroGen, Boehringer Ingelheim, and others, are developing therapies for the Idiopathic Pulmonary Fibrosis treatment
• Emerging Idiopathic Pulmonary Fibrosis therapies in the different phases of clinical trials are- Pamrevlumab, Tipelukast, PLN-74809, HZN-825, Brilaroxazine, PRM-151, C21, TXR 1002, INS018_055, AD-214, AZD5055, LTI-03, CSL312, GB0139, PLN-74809, ENV-101, Pamrevlumab, BI-1015550, and others are expected to have a significant impact on the Idiopathic Pulmonary Fibrosis market in the coming years.
• In April 2025, Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on developing inhaled therapies for life-threatening pulmonary diseases, announced today that AP02 (inhaled nintedanib) was found to be safe and well tolerated in multiple single-ascending dose (SAD) and multiple-ascending dose (MAD) Phase 1 clinical trials involving healthy adult volunteers and patients with idiopathic pulmonary fibrosis (IPF).
• In January 2025, Mediar Therapeutics, Inc., a clinical-stage biotechnology company focused on developing first-in-class therapies to halt fibrosis progression, has announced a global licensing agreement with Eli Lilly and Company to advance MTX-463 into a Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF). MTX-463 is a novel human IgG1 antibody designed to neutralize WISP1-mediated fibrotic signaling in several severe diseases. A recently completed Phase 1 study in healthy volunteers demonstrated that MTX-463 was well-tolerated and successfully engaged WISP1 across all tested doses. The Phase 2 trial, scheduled to begin in the first half of 2025, will evaluate the safety, pharmacokinetics, and efficacy of MTX-463 in IPF patients, with Mediar conducting the trial. Upon completion of Phase 2, Lilly will assume responsibility for further clinical development and commercialization of the program.
• In October 2024, Tvardi Therapeutics, Inc. ("Tvardi"), a clinical-stage biopharmaceutical company specializing in innovative oral small molecule therapies targeting STAT3 for the treatment of fibrosis-driven diseases, announced that its Chief Medical Officer, John Kauh, M.D., will present a poster at the CHEST 2024 Annual Meeting. This event, hosted by the American College of Chest Physicians, takes place from October 6-9 in Boston, Massachusetts. CHEST is recognized globally for its commitment to improving patient outcomes through cutting-edge chest medicine education, clinical research, and collaborative care initiatives.
• In September 2024, Insilico Medicine has reported encouraging preliminary results from its Phase IIa clinical trial of ISM001-055, a small molecule drug developed using generative AI for the treatment of idiopathic pulmonary fibrosis (IPF). The randomized, double-blind, placebo-controlled trial was conducted at 21 sites in China, enrolling 71 patients with IPF. It evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of 12 weeks of oral ISM001-055. The study included four groups: a placebo group, and three treatment groups receiving 30 mg once daily (QD), 30 mg twice daily (BID), and 60 mg QD.
• In July 2024, South Korean biotechnology company Bridge Biotherapeutics has completed enrollment for its Phase II clinical trial of BBT-877, a novel autotaxin inhibitor developed for the treatment of idiopathic pulmonary fibrosis (IPF).
• In May 2024, Aileron Therapeutics has announced positive results from the first cohort of its ongoing Phase Ib clinical trial evaluating inhaled LTI-03 in patients with idiopathic pulmonary fibrosis (IPF). This randomized, double-blind, placebo-controlled, multicenter dose-escalation study includes recently diagnosed IPF patients who have not received anti-fibrotic treatment for at least two months

Idiopathic Pulmonary Fibrosis Overview
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive lung disease characterized by scarring (fibrosis) of lung tissue, leading to breathing difficulties and reduced oxygen exchange. The exact cause is unknown, but risk factors include aging, smoking, and genetic predisposition. Symptoms include shortness of breath, persistent dry cough, and fatigue. There is no cure, but treatments like antifibrotic drugs (pirfenidone, nintedanib) and lung transplantation can help manage the condition.

Get a Free Sample PDF Report to know more about Idiopathic Pulmonary Fibrosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Idiopathic Pulmonary Fibrosis Drugs Under Different Phases of Clinical Development Include:
• Pamrevlumab: FibroGen
• Tipelukast: MediciNova
• PLN-74809: Pliant Therapeutics
• HZN-825: Horizon Pharmaceuticals
• Brilaroxazine: Reviva Pharmaceuticals
• PRM-151: Roche
• C21: Vicore Pharma
• TXR 1002: Aria Pharmaceuticals
• INS018_055: InSilico Medicine
• AD-214: AdAlta
• AZD5055: AstraZeneca
• LTI-03: Lung Therapeutics
• CSL312: CSL Behring
• GB0139: Galecto Biotech AB
• PLN-74809: Pliant Therapeutics
• ENV-101: Endeavor BioMedicine
• Pamrevlumab: FibroGen
• BI-1015550: Boehringer Ingelheim

Idiopathic Pulmonary Fibrosis Route of Administration
Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Idiopathic Pulmonary Fibrosis Molecule Type
Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment
• Idiopathic Pulmonary Fibrosis Assessment by Product Type
• Idiopathic Pulmonary Fibrosis By Stage and Product Type
• Idiopathic Pulmonary Fibrosis Assessment by Route of Administration
• Idiopathic Pulmonary Fibrosis By Stage and Route of Administration
• Idiopathic Pulmonary Fibrosis Assessment by Molecule Type
• Idiopathic Pulmonary Fibrosis by Stage and Molecule Type

DelveInsight's Idiopathic Pulmonary Fibrosis Report covers around 100+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Idiopathic Pulmonary Fibrosis product details are provided in the report. Download the Idiopathic Pulmonary Fibrosis pipeline report to learn more about the emerging Idiopathic Pulmonary Fibrosis therapies
https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Idiopathic Pulmonary Fibrosis Therapeutics Market include:
Key companies developing therapies for Idiopathic Pulmonary Fibrosis are - Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche Ltd, FibroGen Inc., MediciNova Inc., Jubliant Pharma Limited (Jubliant Cadista Limited), Merck & Co. Inc., United Therapeutics, Boehringer Ingelheim International GmbH, Horizon Therapeutics Inc., Avalyn Pharma Inc., CS Pharmaceuticals, and others.

Idiopathic Pulmonary Fibrosis Pipeline Analysis:
The Idiopathic Pulmonary Fibrosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Idiopathic Pulmonary Fibrosis Treatment.
• Idiopathic Pulmonary Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Idiopathic Pulmonary Fibrosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Idiopathic Pulmonary Fibrosis drugs and therapies
https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Idiopathic Pulmonary Fibrosis Pipeline Market Drivers
• Changing lifestyle patterns and increasing consumption of nicotine products, diverse and extensive pipeline therapies, rise in the number of geriatric population are some of the important factors that are fueling the Idiopathic Pulmonary Fibrosis Market.

Idiopathic Pulmonary Fibrosis Pipeline Market Barriers
• However, Lack of effective treatment options for severe Idiopathic Pulmonary Fibrosis (IPF) cases, exact Cause of IPF is not fully understood, misdiagnosis of Idiopathic Pulmonary Fibrosis (IPF) and other factors are creating obstacles in the Idiopathic Pulmonary Fibrosis Market growth.

Scope of Idiopathic Pulmonary Fibrosis Pipeline Drug Insight
• Coverage: Global
• Key Idiopathic Pulmonary Fibrosis Companies: FibroGen, MediciNova, Pliant Therapeutics, Horizon Pharmaceuticals, Reviva Pharmaceuticals, Roche, Vicore Pharma, Aria Pharmaceuticals, InSilico Medicine, AdAlta, AstraZeneca, Lung Therapeutics, CSL Behring, Galecto Biotech AB, Pliant Therapeutics, Endeavor BioMedicine, FibroGen, Boehringer Ingelheim, and others
• Key Idiopathic Pulmonary Fibrosis Therapies: Pamrevlumab, Tipelukast, PLN-74809, HZN-825, Brilaroxazine, PRM-151, C21, TXR 1002, INS018_055, AD-214, AZD5055, LTI-03, CSL312, GB0139, PLN-74809, ENV-101, Pamrevlumab, BI-1015550, and others
• Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Idiopathic Pulmonary Fibrosis current marketed and Idiopathic Pulmonary Fibrosis emerging therapies
• Idiopathic Pulmonary Fibrosis Market Dynamics: Idiopathic Pulmonary Fibrosis market drivers and Idiopathic Pulmonary Fibrosis market barriers

Request for Sample PDF Report for Idiopathic Pulmonary Fibrosis Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Idiopathic Pulmonary Fibrosis Report Introduction
2. Idiopathic Pulmonary Fibrosis Executive Summary
3. Idiopathic Pulmonary Fibrosis Overview
4. Idiopathic Pulmonary Fibrosis- Analytical Perspective In-depth Commercial Assessment
5. Idiopathic Pulmonary Fibrosis Pipeline Therapeutics
6. Idiopathic Pulmonary Fibrosis Late Stage Products (Phase II/III)
7. Idiopathic Pulmonary Fibrosis Mid Stage Products (Phase II)
8. Idiopathic Pulmonary Fibrosis Early Stage Products (Phase I)
9. Idiopathic Pulmonary Fibrosis Preclinical Stage Products
10. Idiopathic Pulmonary Fibrosis Therapeutics Assessment
11. Idiopathic Pulmonary Fibrosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Idiopathic Pulmonary Fibrosis Key Companies
14. Idiopathic Pulmonary Fibrosis Key Products
15. Idiopathic Pulmonary Fibrosis Unmet Needs
16 . Idiopathic Pulmonary Fibrosis Market Drivers and Barriers
17. Idiopathic Pulmonary Fibrosis Future Perspectives and Conclusion
18. Idiopathic Pulmonary Fibrosis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Idiopathic Pulmonary Fibrosis Market https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Idiopathic Pulmonary Fibrosis Epidemiology https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Idiopathic Pulmonary Fibrosis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Dengue Fever Market: https://www.delveinsight.com/report-store/dengue-fever-market
• Chronic Hemodialysis Market: https://www.delveinsight.com/report-store/chronic-hemodialysis-market
• Brucellosis Market: https://www.delveinsight.com/report-store/brucellosis-market
• Childhood Atropine For Myopia Progression Market: https://www.delveinsight.com/sample-request/childhood-atropine-for-myopia-progression-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Cardiac Rhythm Management Devices Market: https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market
• Tumor Ablation Market: https://www.delveinsight.com/report-store/tumor-ablation-market
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.